Pfizer granted Takeda rights to co-market tofacitinib (formerly tasocitinib) in Japan for rheumatoid arthritis and other undisclosed indications

Pfizer Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Takeda Pharmaceutical Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced